PHT Corporation’s Market Leading LogPad And StudyWorksTM EPRO Solutions Used In Sanofi Pasteur’s Phase II Study Of New Clostridium Difficile Vaccine

PHT Corporation announced that Sanofi Pasteur is using PHT’s LogPad® System and StudyWorksTM online gateway by reason of a Phase II test to develop a vaccine for the Clostridium difficile bacterium. PHT is the leading provider of ePRO solutions used in pharmaceutical and biotechnology clinical trials worldwide. Sanofi Pasteur, a world conductor in the vaccines industry, is the vaccines separation of the sanofi-aventis Group.

Sanofi Pasteur is acting by PHT Corporation to collect direct apprehension patient experience data quickly, safely and accurately at medical centers transversely the United Kingdom and the United States. Sanofi Pasteur’s appearance IIb case plans to study over 600 vulgar herd with some acute infection caused by C. difficile. The bacterium spreads through the human intestinal system causing diarrhea, fever, qualm, ventral annoy, and staid of the intestines conditions such as colitis, that can result in death.

Vicki Tyler, a Clinical Trial Manager at Sanofi Pasteur’session Massachusetts advantage, explained that, unlike with a paper chronicle, sites and sponsors know they are receiving real-time essay data whenever using the LogPad. Sanofi Pasteur has used PHT’s ePRO solutions successfully for other trials and expects to achieve specific improvements in the data gathering processes, facts kind, patient compliance, and trial measure efficiency by using the LogPad instead of newspaper for this testing.

PHT Vice President of Marketing and Product Management Sheila Rocchio said, “With paper diaries, researchers can only hope that patients remember to complete their diaries. When patients comply, the data are not completed and often inaccurate. PHT’s LogPad time-stamps all facts entries, providing an unmediated given conditions advantage upper paper. Using ePRO promotes safety and exactness in studies, enabling sponsors to bring new drugs to place of traffic faster and more economically.”

Source
PHT Corporation

December 26 2009 04:52 am | Immune System

Comments are closed.